Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate

被引：92

作者：

Hosking, David ^{[1
]}

Lyles, Kenneth

Brown, Jacques P.

Fraser, William D.

Miller, Paul

Curiel, Manuel Diaz

Devogelaer, Jean-Pierre

Hooper, Michael

Su, Guoqin

Zelenakas, Ken

Pak, Judy

Fashola, Taiwo

Saidi, Youssef

Eriksen, Erik Fink

Reid, Ian R.

机构：

[1] City Hosp, Nottingham NG5 1PB, England

[2] Duke Univ, Med Ctr, VA Med Ctr, Durham, NC 27706 USA

[3] CHU Quebec, Ste Foy, PQ G1V 2M3, Canada

[4] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England

[5] Colorado Ctr Bone Res, Lakewood, CO USA

[6] Univ Autonoma Madrid, Fdn Jimenez Diaz, Madrid 34, Spain

[7] Catholic Univ Louvain, B-1200 Brussels, Belgium

[8] Univ Sydney, Sydney, NSW 2006, Australia

[9] Novartis Pharmaceut, E Hanover, NJ USA

[10] Novartis Pharma AG, Basel, Switzerland

[11] Univ Auckland, Auckland 1, New Zealand

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2007年 / 22卷 / 01期

关键词：

Paget's disease; bone turnover; remission; zoledronic acid; risedronate;

D O I：

10.1359/JBMR.061001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A single 5-mg infusion of zoledronic acid restores biochemical markers of bone turnover into the reference range in the majority of patients with Paget's disease and maintains biochemical remission for at least 2 years. This effect is largely independent of pretreatment disease activity and prior bisphosphonate therapy.

引用

页码：142 / 148

页数：7

共 28 条

[1] Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone [J].